Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans.

AKT1-dependent molecular pathways control diverse aspects of cellular development and adaptation, including interactions with neuronal dopaminergic signaling. If AKT1 has an impact on dopaminergic signaling, then genetic variation in AKT1 would be associated with brain phenotypes related to cortical dopaminergic function. Here, we provide evidence that a coding variation in AKT1 that affects protein expression in human B lymphoblasts influenced several brain measures related to dopaminergic function. Cognitive performance linked to frontostriatal circuitry, prefrontal physiology during executive function, and frontostriatal gray-matter volume on MRI were altered in subjects with the AKT1 variation. Moreover, on neuroimaging measures with a main effect of the AKT1 genotype, there was significant epistasis with a functional polymorphism (Val158Met) in catechol-O-methyltransferase [COMT], a gene that indexes cortical synaptic dopamine. This genetic interaction was consistent with the putative role of AKT1 in dopaminergic signaling. Supportive of an earlier tentative association of AKT1 with schizophrenia, we also found that this AKT1 variant was associated with risk for schizophrenia. These data implicate AKT1 in modulating human prefrontal-striatal structure and function and suggest that the mechanism of this effect may be coupled to dopaminergic signaling and relevant to the expression of psychosis.

[1]  Vladimir I. Vladimirov,et al.  AKT1 Is Associated with Schizophrenia Across Multiple Symptom Dimensions in the Irish Study of High Density Schizophrenia Families , 2008, Biological Psychiatry.

[2]  A. Meyer-Lindenberg,et al.  Catechol-O-Methyltransferase Val158Met Modulation of Prefrontal–Parietal–Striatal Brain Systems during Arithmetic and Temporal Transformations in Working Memory , 2007, The Journal of Neuroscience.

[3]  A. Morris,et al.  Fine mapping versus replication in whole-genome association studies. , 2007, American journal of human genetics.

[4]  Joseph A. Gogos,et al.  Site-Specific Role of Catechol-O-Methyltransferase in Dopamine Overflow within Prefrontal Cortex and Dorsal Striatum , 2007, The Journal of Neuroscience.

[5]  Terry E. Goldberg,et al.  Factor analysis of neurocognitive tests in a large sample of schizophrenic probands, their siblings, and healthy controls , 2007, Schizophrenia Research.

[6]  Andreas Meyer-Lindenberg,et al.  Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function , 2007, Proceedings of the National Academy of Sciences.

[7]  M. Owen,et al.  Association analysis of AKT1 and schizophrenia in a UK case control sample , 2007, Schizophrenia Research.

[8]  R. Burke.  Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: Two approaches with therapeutic potential in the treatment of neurodegenerative disease. , 2007, Pharmacology & therapeutics.

[9]  Eve C. Johnstone,et al.  Relationship of Catechol-O-Methyltransferase Variants to Brain Structure and Function in a Population at High Risk of Psychosis , 2007, Biological Psychiatry.

[10]  T. Robbins,et al.  Catechol O-Methyltransferase val158met Genotype Influences Frontoparietal Activity during Planning in Patients with Parkinson's Disease , 2007, The Journal of Neuroscience.

[11]  Michael F Egan,et al.  Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects , 2007, Neuropsychopharmacology.

[12]  J. Gold,et al.  Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. , 2007, Archives of general psychiatry.

[13]  M. Egan,et al.  Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms , 2007, Molecular Psychiatry.

[14]  R. Gainetdinov,et al.  The Akt-GSK-3 signaling cascade in the actions of dopamine. , 2007, Trends in pharmacological sciences.

[15]  Eden R Martin,et al.  No gene is an island: the flip-flop phenomenon. , 2007, American journal of human genetics.

[16]  Andreas Meyer-Lindenberg,et al.  Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. , 2007, The Journal of clinical investigation.

[17]  J. Javitch,et al.  Dopamine Transporter Activity Mediates Amphetamine-Induced Inhibition of Akt through a Ca2+/Calmodulin-Dependent Kinase II-Dependent Mechanism , 2007, Molecular Pharmacology.

[18]  Graham V. Williams,et al.  Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory , 2007, Nature Neuroscience.

[19]  I. Levav,et al.  Cancer risk among parents and siblings of patients with schizophrenia , 2007, British Journal of Psychiatry.

[20]  D. Theobald,et al.  IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates , 2007, Nature Neuroscience.

[21]  P. Pavlidis,et al.  Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning , 2006, Proceedings of the National Academy of Sciences.

[22]  R. O’Reilly.  Biologically Based Computational Models of High-Level Cognition , 2006, Science.

[23]  T. Asada,et al.  Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia , 2006, Journal of neurochemistry.

[24]  A. Meyer-Lindenberg,et al.  Intermediate phenotypes and genetic mechanisms of psychiatric disorders , 2006, Nature Reviews Neuroscience.

[25]  R. Coppola,et al.  Prefrontal Electrophysiologic “Noise” and Catechol-O-Methyltransferase Genotype in Schizophrenia , 2006, Biological Psychiatry.

[26]  Daniel R. Weinberger,et al.  Schizophrenia Genes - Famine to Feast , 2006, Biological Psychiatry.

[27]  M. R. Sargolzaee,et al.  Association of AKT1 haplotype with the risk of schizophrenia in Iranian population , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[28]  Tommaso Scarabino,et al.  Additive Effects of Genetic Variation in Dopamine Regulating Genes on Working Memory Cortical Activity in Human Brain , 2006, The Journal of Neuroscience.

[29]  S. Faraone,et al.  Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population , 2006, Psychiatric genetics.

[30]  Boris S. Gutkin,et al.  Dopamine modulation in the basal ganglia locks the gate to working memory , 2006, Journal of Computational Neuroscience.

[31]  B. Pappas,et al.  Selective acetylcholine and dopamine lesions in neonatal rats produce distinct patterns of cortical dendritic atrophy in adulthood , 2005, Neuroscience.

[32]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[33]  A. Levine,et al.  Detection of functional single-nucleotide polymorphisms that affect apoptosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Stephan Eliez,et al.  COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome , 2005, Nature Neuroscience.

[35]  M. Chee,et al.  fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. , 2005, The American journal of psychiatry.

[36]  W. Maier,et al.  Further Evidence for Association of Variants in the AKT1 Gene with Schizophrenia in a Sample of European Sib-Pair Families , 2005, Biological Psychiatry.

[37]  T. Sotnikova,et al.  An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.

[38]  D. Glahn,et al.  Beyond hypofrontality: A quantitative meta‐analysis of functional neuroimaging studies of working memory in schizophrenia , 2005, Human brain mapping.

[39]  R. Nussbaum,et al.  Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype , 2005, Nature Neuroscience.

[40]  Matti Laine,et al.  Frontal and Temporal Dopamine Release during Working Memory and Attention Tasks in Healthy Humans: a Positron Emission Tomography Study Using the High-Affinity Dopamine D2 Receptor Ligand [11C]FLB 457 , 2005, The Journal of Neuroscience.

[41]  N. Rajakumar,et al.  Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum , 2005, Biological Psychiatry.

[42]  A. Meyer-Lindenberg,et al.  The Brain-derived Neurotrophic Factor Val66met Polymorphism and Variation in Human Cortical Morphology , 2022 .

[43]  M. Egan,et al.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. , 2004, American journal of human genetics.

[44]  M. Ikeda,et al.  Association of AKT1 with schizophrenia confirmed in a Japanese population , 2004, Biological Psychiatry.

[45]  D. Weinberger,et al.  Genes, dopamine and cortical signal-to-noise ratio in schizophrenia , 2004, Trends in Neurosciences.

[46]  J. Seamans,et al.  The principal features and mechanisms of dopamine modulation in the prefrontal cortex , 2004, Progress in Neurobiology.

[47]  P. Thompson,et al.  Neurobiology of intelligence: science and ethics , 2004, Nature Reviews Neuroscience.

[48]  T. Sotnikova,et al.  Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Goldman-Rakic,et al.  Selective D2 Receptor Actions on the Functional Circuitry of Working Memory , 2004, Science.

[50]  M. Karayiorgou,et al.  Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.

[51]  M. Egan,et al.  Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. , 2003, The American journal of psychiatry.

[52]  M. Laruelle,et al.  Glutamate, Dopamine, and Schizophrenia , 2003 .

[53]  R. Gur,et al.  Working memory deficit as a core neuropsychological dysfunction in schizophrenia. , 2003, The American journal of psychiatry.

[54]  M. Egan,et al.  Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Egan,et al.  Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. , 2003, The American journal of psychiatry.

[56]  B. Kolachana,et al.  Catechol-O-Methyltransferase Genotype and Dopamine Regulation in the Human Brain , 2003, The Journal of Neuroscience.

[57]  C. Chabris,et al.  Neural mechanisms of general fluid intelligence , 2003, Nature Neuroscience.

[58]  M. Laruelle,et al.  Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. , 2003, Annals of the New York Academy of Sciences.

[59]  R. Engle,et al.  The role of prefrontal cortex in working-memory capacity, executive attention, and general fluid intelligence: An individual-differences perspective , 2002, Psychonomic bulletin & review.

[60]  J. Cummings,et al.  Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. , 2002, The Journal of neuropsychiatry and clinical neurosciences.

[61]  Thomas E. Nichols,et al.  Thresholding of Statistical Maps in Functional Neuroimaging Using the False Discovery Rate , 2002, NeuroImage.

[62]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[63]  T. Goldberg,et al.  Dopaminergic modulation of cortical function in patients with Parkinson's disease , 2002, Annals of neurology.

[64]  Daniel R. Weinberger,et al.  Prefrontal neurons and the genetics of schizophrenia , 2001, Biological Psychiatry.

[65]  P. Greengard.  The neurobiology of slow synaptic transmission. , 2001, Science.

[66]  Michael F Egan,et al.  Relative risk for cognitive impairments in siblings of patients with schizophrenia , 2001, Biological Psychiatry.

[67]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Cohen,et al.  Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. , 2001, Archives of general psychiatry.

[69]  Newell,et al.  A neural basis for general intelligence , 2000, American journal of ophthalmology-glaucoma.

[70]  Tyrone D. Cannon,et al.  The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. , 2000, American journal of human genetics.

[71]  R. Dixon,et al.  Age-related cognitive deficits mediated by changes in the striatal dopamine system. , 2000, The American journal of psychiatry.

[72]  Gonçalo R. Abecasis,et al.  GOLD-Graphical Overview of Linkage Disequilibrium , 2000, Bioinform..

[73]  T. Robbins,et al.  Frontal-striatal cognitive deficits in patients with chronic schizophrenia. , 1997, Brain : a journal of neurology.

[74]  J. Harvey,et al.  New evidence for neurotransmitter influences on brain development , 1997, Trends in Neurosciences.

[75]  T. Salthouse.  The processing-speed theory of adult age differences in cognition. , 1996, Psychological review.

[76]  Karl J. Friston,et al.  A unified statistical approach for determining significant signals in images of cerebral activation , 1996, Human brain mapping.

[77]  P. Goldman-Rakic,et al.  Modulation of memory fields by dopamine Dl receptors in prefrontal cortex , 1995, Nature.

[78]  G. E. Alexander,et al.  Parallel organization of functionally segregated circuits linking basal ganglia and cortex. , 1986, Annual review of neuroscience.